Subcutaneous Versus Intravenous Morphine When Switching From Oral to Parenteral Route in Palliative Cancer Patients

NCT05236647 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Pain Cancer

Interventions

DRUG: Morphine

Sponsor

University Hospital, Akershus